Order:
  1.  21
    GlaxoSmithKline and Access to Essential Medicines (B).N. Craig Smith & Anne Duncan - 2005 - Journal of Business Ethics Education 2 (1):123-132.
    The (B) case summarizes GSK’s response to pressures to increase access to essential medicines in developing countries and subsequent developments.
    Direct download (5 more)  
     
    Export citation  
     
    My bibliography   2 citations  
  2.  32
    GlaxoSmithKline and Developing Country Access to Essential Medicines (A).N. Craig Smith & Anne Duncan - 2005 - Journal of Business Ethics Education 2 (1):97-121.
    The merger of GlaxoWellcome and SmithKlineBeecham in 2000 created the world’s second largest pharmaceutical company, GlaxoSmithKline. GSK also became the world’s leader in the provision of drugs to treat the three most critical diseases in the developing world: HIV/AIDS, malaria and tuberculosis. In addition to merger related strategy and restructuring activities, the company finds itself having to respond to pressures to increase access to these essential medicines in developing countries, including the possibility of major reductions in price. How should GSK (...)
    Direct download (7 more)  
     
    Export citation  
     
    My bibliography  
  3.  2
    GlaxoSmithKline and Access to Essential Medicines.N. Craig Smith & Anne Duncan - 2005 - Journal of Business Ethics Education 2 (1):123-132.
    The case summarizes GSK’s response to pressures to increase access to essential medicines in developing countries and subsequent developments.
    Direct download  
     
    Export citation  
     
    My bibliography  
  4. GlaxoSmithKline and Developing Country Access to Essential Medicines.N. Craig Smith & Anne Duncan - 2005 - Journal of Business Ethics Education 2 (1):97-121.
    The merger of GlaxoWellcome and SmithKlineBeecham in 2000 created the world’s second largest pharmaceutical company, GlaxoSmithKline. GSK also became the world’s leader in the provision of drugs to treat the three most critical diseases in the developing world: HIV/AIDS, malaria and tuberculosis. In addition to merger related strategy and restructuring activities, the company finds itself having to respond to pressures to increase access to these essential medicines in developing countries, including the possibility of major reductions in price. How should GSK (...)
    Direct download  
     
    Export citation  
     
    My bibliography